A US judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

A new expert review endorses GLP-1 RAs and other medications for sustainable weight loss in children with obesity and MASLD.

How long it takes to lose weight can vary based on a number of factors, such as age, medications you take, your activity ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...